SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 20, 2004--Tularik Inc. (Nasdaq: TLRK - News) will host a live webcast of its conference call discussing the Company's 2004 first quarter financial results at 4:30 p.m. Eastern Time on April 22, 2004. The call will be hosted by David V. Goeddel, Ph.D., Chief Executive Officer. Tularik will issue a press release regarding the 2004 first quarter financial results after the market closes on April 22, 2004.
The press release and the live webcast can be accessed by visiting Tularik's Internet website at www.tularik.com under the "Investors/Media" tab. Following the webcast, an archived version of the call will be available at the same address for five days.
Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. The Company's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma (HCC) and Phase 2 clinical trials of T607 for the treatment of gastric cancer and esophageal cancer. T487, for the treatment of psoriasis, and T131, for the treatment of type 2 diabetes, are in Phase 2 clinical trials. T487 for the treatment of rheumatoid arthritis is moving into Phase 2 clinical trials. T71 for the treatment of obesity is in Phase 1 clinical trials. A corporate partner, Eli Lilly and Company, is conducting a Phase 2 clinical trial of an oral Factor Xa inhibitor for the prevention and treatment of thrombotic diseases. For more information, visit Tularik's Internet website at www.tularik.com.
Tularik Inc. Alicia Williams (Investors/Media), 650-825-7322
Source: Tularik Inc.